Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Ponatinib launched for chronic myeloid and acute lymphoblastic leukaemias

By News team

Patients with certain types of leukaemia now have the option of being treated with ponatinib.

The new medicine is indicated for adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib; who are intolerant of dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; as well as those who have the T3151 mutation. It is also indicated for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatanib; who are intolerant of dasatanib and for whom subsequent treatment with imatinib is not appropriate; or who have the T3151 mutation.

The medicine received a positive recommendation from the European Medicines Agency in March 2013. However, ponatinib’s manufacturer Ariad Pharma told PJ Online that the EMA is currently reviewing safety data regarding a potential increased risk of blood clots associated with the medicine.

Ponatinib is a tyrosine kinase inhibitor with activity against the BCR-ABL protein. The most common side effects are decreased platelet count, rash, dry skin and abdominal pain.

Ponatinib is marketed as Iclusig by Ariad.

Product details

Action: Tyrosine kinase inhibitor of the BCR-ABL protein

Dose: Recommended starting dose is 45mg once daily until disease progression or unacceptable toxicity. To manage toxicity the dose can be adjusted to 15mg or 30mg once daily.

Legal category: POM

Price: 60 x 15mg tablets, or 30 x 45mg tablets, £5,050 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11129916

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.